Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia

doi:10.3324/haematol.2018.205955

. 2019 May;104(5):868-871.

doi: 10.3324/haematol.2018.205955. Epub 2019 Mar 28.

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia

Ross L Levine^{1

2}, Peter J M Valk^{1

2}

Affiliations

¹ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA leviner@mskcc.org p.valk@erasmusmc.nl.
² Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands leviner@mskcc.org p.valk@erasmusmc.nl.

PMID: 30923100
PMCID: PMC6518900
DOI: 10.3324/haematol.2018.205955

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia

Ross L Levine et al. Haematologica. 2019 May.

. 2019 May;104(5):868-871.

doi: 10.3324/haematol.2018.205955. Epub 2019 Mar 28.

Authors

Ross L Levine^{1

2}, Peter J M Valk^{1

2}

Affiliations

¹ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA leviner@mskcc.org p.valk@erasmusmc.nl.
² Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands leviner@mskcc.org p.valk@erasmusmc.nl.

PMID: 30923100
PMCID: PMC6518900
DOI: 10.3324/haematol.2018.205955

No abstract available

PubMed Disclaimer

Cited by

Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Carrillo-Cruz E, Bilbao-Sieyro C, Prados de la Torre E, Martínez-Cuadrón D, Rodríguez-Veiga R, Boluda B, Gil C, Bernal T, Bergua JM, Algarra L, Tormo M, Martínez-Sánchez P, Soria E, Serrano J, Alonso-Domínguez JM, García-Boyero R, Amigo ML, Herrera-Puente P, Sayas MJ, Lavilla-Rubira E, Martínez-López J, Calasanz MJ, García-Sanz R, Pérez-Simón JA, Gómez-Casares MT, Sánchez-García J, Barragán E, Montesinos P, On Behalf Of Pethema Group. Sargas C, et al. Cancers (Basel). 2023 Jan 10;15(2):438. doi: 10.3390/cancers15020438. Cancers (Basel). 2023. PMID: 36672386 Free PMC article.
Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia.
Hasserjian RP, Steensma DP, Graubert TA, Ebert BL. Hasserjian RP, et al. Blood. 2020 May 14;135(20):1729-1738. doi: 10.1182/blood.2019004770. Blood. 2020. PMID: 32232484 Free PMC article. Review.
A comparative study of next-generation sequencing and fragment analysis for the detection and allelic ratio determination of FLT3 internal tandem duplication.
Kim JJ, Lee KS, Lee TG, Lee S, Shin S, Lee ST. Kim JJ, et al. Diagn Pathol. 2022 Jan 26;17(1):14. doi: 10.1186/s13000-022-01202-x. Diagn Pathol. 2022. PMID: 35081962 Free PMC article.
Integrating clinical features with genetic factors enhances survival prediction for adults with acute myeloid leukemia.
Silveira DRA, Quek L, Santos IS, Corby A, Coelho-Silva JL, Pereira-Martins DA, Vallance G, Brown B, Nardinelli L, Silva WF, Velloso EDRP, Lucena-Araujo AR, Traina F, Peniket A, Vyas P, Rego EM, Bendit I, Rocha V. Silveira DRA, et al. Blood Adv. 2020 May 26;4(10):2339-2350. doi: 10.1182/bloodadvances.2019001419. Blood Adv. 2020. PMID: 32453839 Free PMC article.
Minimal residual disease and stem cell transplantation outcomes.
Cloos J, Ossenkoppele GJ, Dillon R. Cloos J, et al. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):617-625. doi: 10.1182/hematology.2019000006. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808862 Free PMC article. Review.

See all "Cited by" articles

References

1. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. - PMC - PubMed
1. Onecha E, Linares M, Rapado I, et al. Novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. Haematologica. 2018;104(2):288–296. - PMC - PubMed
1. Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5(2):96–102. - PMC - PubMed
1. Schranz K, Hubmann M, Harin E, et al. Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia. Oncotarget. 2018;9(53): 30128–30145. - PMC - PubMed
1. Levis MJ, Perl AE, Altman JK, et al. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv. 2018;2(8):825–831. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. - PMC - PubMed

[2] Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. - PMC - PubMed

[3] Onecha E, Linares M, Rapado I, et al. Novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. Haematologica. 2018;104(2):288–296. - PMC - PubMed

[4] Onecha E, Linares M, Rapado I, et al. Novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. Haematologica. 2018;104(2):288–296. - PMC - PubMed

[5] Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5(2):96–102. - PMC - PubMed

[6] Murphy KM, Levis M, Hafez MJ, et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. 2003;5(2):96–102. - PMC - PubMed

[7] Schranz K, Hubmann M, Harin E, et al. Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia. Oncotarget. 2018;9(53): 30128–30145. - PMC - PubMed

[8] Schranz K, Hubmann M, Harin E, et al. Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia. Oncotarget. 2018;9(53): 30128–30145. - PMC - PubMed

[9] Levis MJ, Perl AE, Altman JK, et al. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv. 2018;2(8):825–831. - PMC - PubMed

[10] Levis MJ, Perl AE, Altman JK, et al. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv. 2018;2(8):825–831. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia

Affiliations

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia

Authors

Affiliations

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical